HomeCompareTGI vs ABBV

TGI vs ABBV: Dividend Comparison 2026

TGI yields 7.69% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $83.7K in total portfolio value
10 years
TGI
TGI
● Live price
7.69%
Share price
$26.01
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.0K
Annual income
$0.80
Full TGI calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — TGI vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTGIABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TGI + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TGI pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TGI
Annual income on $10K today (after 15% tax)
$653.59/yr
After 10yr DRIP, annual income (after tax)
$0.68/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, ABBV beats the other by $21,866.19/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TGI + ABBV for your $10,000?

TGI: 50%ABBV: 50%
100% ABBV50/50100% TGI
Portfolio after 10yr
$62.9K
Annual income
$12,863.26/yr
Blended yield
20.46%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

TGI
Analyst Ratings
13
Buy
12
Hold
4
Sell
Consensus: Buy
Price Target
$15.71
-39.6% upside vs current
Range: $12.00 — $20.00
Altman Z
1.6
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TGI buys
0
ABBV buys
0
No recent congressional trades found for TGI or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTGIABBV
Forward yield7.69%3.12%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%40.6%
Portfolio after 10y$21.0K$104.7K
Annual income after 10y$0.80$25,725.73
Total dividends collected$786.00$63.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy
Analyst price target$15.71$256.15

Year-by-year: TGI vs ABBV ($10,000, DRIP)

YearTGI PortfolioTGI Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,084$384.47$11,559$438.51$475.00ABBV
2$12,060$199.14$13,494$640.86$1.4KABBV
3$13,005$101.24$15,951$945.97$2.9KABBV
4$13,966$51.02$19,152$1,413.89$5.2KABBV
5$14,970$25.60$23,443$2,146.38$8.5KABBV
6$16,030$12.82$29,391$3,321.96$13.4KABBV
7$17,159$6.42$37,948$5,265.87$20.8KABBV
8$18,363$3.21$50,795$8,596.74$32.4KABBV
9$19,650$1.61$71,034$14,549.41$51.4KABBV
10$21,026$0.80$104,715$25,725.73$83.7KABBV

TGI vs ABBV: Complete Analysis 2026

TGIStock

Triumph Group, Inc. designs, engineers, manufactures, repairs, overhauls, and distributes aerostructures, aircraft components, accessories, subassemblies, and systems worldwide. It operates in two segments, Triumph Systems & Support, and Triumph Aerospace Structures. The company offers aircraft and engine-mounted accessory drives, thermal control systems and components, cargo hooks, high lift actuations, cockpit control levers, hydraulic systems and components, control system valve bodies, landing gear actuation systems, electronic engine controls, landing gear components and assemblies, exhaust nozzles and ducting, main engine gearbox assemblies, geared transmissions and drive train components, main fuel pumps, fuel-metering units, primary and secondary flight control systems, and vibration absorbers. It also designs, manufactures, and repairs composite and metal bonding, flight control surfaces, engine nacelles, empennages, wing flaps, acoustic and thermal insulation systems, and composite ducts and floor panels, as well as provides integrated testing and certification services; and fuselage panels, horizontal and vertical tails, and floor grids. In addition, the company offers air cycle machines, blades and vanes, auxiliary power units, constant speed drives, combustors, engine and airframe accessories, stators, flight control surfaces, transition ducts, integrated drive generators, sidewalls, nacelles, light assemblies, remote sensors, overhead bins, thrust reversers, and fuel bladder cells, as well as cabin panes, shades, light lenses, and other components. It serves original equipment manufacturers of commercial, regional, and military aircraft; and aircraft components, as well as business jets and regional airlines, and air cargo carriers. Triumph Group, Inc. was incorporated in 1993 and is headquartered in Berwyn, Pennsylvania.

Full TGI Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this TGI vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TGI vs SCHDTGI vs JEPITGI vs OTGI vs KOTGI vs MAINTGI vs JNJTGI vs MRKTGI vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.